Olufunmilayo Olopade to Antineoplastic Agents
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Antineoplastic Agents.
Connection Strength
0.681
-
Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
Score: 0.215
-
Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer. 2013 Apr; 13(2):156-8.
Score: 0.191
-
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
Score: 0.071
-
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
Score: 0.058
-
Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23.
Score: 0.048
-
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68.
Score: 0.047
-
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
Score: 0.045
-
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
Score: 0.005